Calcium Sleep Quality Randomized Trial: What the Evidence Says

Quick Answer

Calcium Sleep Quality Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are guideline, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 guideline, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Recently, pregabalin was found to interact only with the molecular site α2δ-1, which was also believed as the only relevant functional site of pregabalin. [Lu Hui (2026); evidence level 2]
• Anxiety and depressive disorders frequently co-occur, and converging evidence from symptom profiles, longitudinal course, shared neurobiological markers, familial aggregation, and treatment response supports a substantial overlap between these conditions. [Derkaczew Maria (2026); evidence level 4]
• Importantly, even agents considered comparatively "benign", such as non-benzodiazepine anxiolytics, may rarely cause significant neurological adverse effects in vulnerable individuals, as illustrated by reports of buspirone-associated dyskinesia or dystonia, plausibly related to its interactions with dopaminergic signaling. [Derkaczew Maria (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For calcium sleep quality randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Lu Hui (2026). Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain. DOI: 10.1002/cns.70866. PMCID: PMC13275550. PMID: 42310848. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13275550/
• Derkaczew Maria (2026). Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review. DOI: 10.3390/cells15110970. PMCID: PMC13256961. PMID: 42274562. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256961/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.